Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
Our products never contain phosphates, chlorine, ammonia, or brighteners
Ideal For: Patients with: Leaky Gut Syndrome, IBS, IBD (Crohns, Ulcerative Colitis), acid reflux, stomach ulcers, or general digestive inflammation
How is a NAD+ injection different from a NAD+ IV drip
Available at: (Accessed 24 November 2022)